ctDNA-Informed Management of Early-Stage Rectal Cancer

ctDNA-Informed Management of Early-Stage Rectal Cancer is a phase 2, interventional study registered as NCT07209215 by University of California, Davis, with a registry enrolment figure of 200 participants, started 2026-10 and due to reach its primary completion in 2028-05. Interventions recorded: Signatera Genome ultra-sensitive ctDNA blood test + total neoadjuvant therapy (TNT). Conditions listed: Rectal Adenocarcinoma; Rectal Cancer; Early-stage Rectal Cancer; Locally Advanced Rectal Adenocarcinoma. Primary outcome: Pathologic complete response (pathCR) rate (ctDNA Informed Management Arm); Pathologic complete response (pathCR) rate (Post TNT SOC Surgery Arm); Disease-free survival (DFS) rate (ctDNA Informed Management Arm). Colorectal eligibility wording from the registry: "* Tumor tissue histologically confirming rectal adenocarcinoma that is available for Natera ctDNA assay". Sites: United States. No results are recorded here; the registry entry is the source.